Identification of cysteinyl-leukotriene-receptor 1 antagonists as ligands for the bile acid receptor GPBAR1-Reference-Cited by-同舟云学术

Identification of cysteinyl-leukotriene-receptor 1 antagonists as ligands for the bile acid receptor GPBAR1

Published:2020-07 Issue: Volume:177 Page:113987
ISSN:0006-2952
Container-title:Biochemical Pharmacology
language:en
Short-container-title:Biochemical Pharmacology

Author:

Biagioli Michele,Carino Adriana,Marchianò Silvia,Roselli Rosalinda,Di Giorgio Cristina,Bordoni Martina,Fiorucci Chiara,Sepe Valentina,Conflitti Paolo,Limongelli Vittorio,Distrutti Eleonora,Baldoni Monia,Zampella Angela,Fiorucci Stefano

Funder

Italian MIUR-PRIN 2017

Swiss National Science Foundatio

COST

Publisher

Elsevier BV

Subject

Pharmacology,Biochemistry

Reference63 articles.

1. 5-Lipoxygenase, a key enzyme for leukotriene biosynthesis in health and disease;Rådmark;Biochim. Biophys. Acta,2015

2. Leukotrienes;Peters-Golden;N. Engl. J. Med.,2007

3. Cysteinyl leukotriene receptors;Evans;Prostaglandins Other Lipid Mediat.,2002

4. Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7;Bäck;Br. J. Pharmacol.,2014

5. The Role of Leukotrienes as Potential Therapeutic Targets in Allergic Disorders;Jo-Watanabe;Int. J. Mol. Sci.,2019

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A microbial derived bile acid acts as GPBAR1 agonist and RORγt inverse agonist and reverses inflammation in inflammatory bowel disease;2024-04-11

2. The role of human 5-Lipoxygenase (5-LO) in carcinogenesis - a question of canonical and non-canonical functions;Oncogene;2024-04-04

3. Bile acids and their receptors in regulation of gut health and diseases;Progress in Lipid Research;2023-01

4. Combinatorial targeting of G‐protein‐coupled bile acid receptor 1 and cysteinyl leukotriene receptor 1 reveals a mechanistic role for bile acids and leukotrienes in drug‐induced liver injury;Hepatology;2022-10-12

5. Chlorogenic acid attenuates inflammation in LPS-induced Human gingival fibroblasts via CysLT1R/Nrf2/NLRP3 signaling;International Immunopharmacology;2022-06